1374203-75-4

Upstream product

• 62-23-7 4-nitro-benzoic acid 
• 55121-99-8 (4-aminophenyl)(4-methylpiperazin-1-yl)methanone 
• 367-24-8 4-bromo-2-fluoroaniline 
• 101080-38-0 N-(2-bromophenyl)-2-isonitrosoacetanilide 
• 615-36-1 2-bromoaniline 
• 1374208-26-0 1-(4-bromo-phenyl)-3-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-urea 
• 1332327-18-0 1-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-urea 
• 21091-98-5 (4-methylpiperazin-1-yl)(4-nitrophenyl)methanone 
• 20780-74-9 7-bromoisatin 

Relevant academic research and scientific papers

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.